Biologics

Theradaptive's Osteo-Adapt SP spinal fusion implant received the FDA's breakthrough medical device designation, according to a Nov. 19 news release.

Pacira Biosciences completed its acquisition of Flexion Therapeutics, according to a Nov. 19 news release.

Orthobiologics company Bioventus has signed a lease agreement to double its current operations and manufacturing space in Cordova, Tenn.

A spine biologics company's $100 million investment deal and six more key updates in regenerative medicine in the last two months:

Houston-based FibroBiologics, a regenerative medicine company developing treatments for chronic disease using fibroblast cells, signed an agreement with a private investment group that will provide the company with up to $100 million over the next three years.

The number of businesses and medical clinics advertising stem cell-based therapies has skyrocketed in the U.S. over the past five years, according to a study published in Cell Stem Cell Nov. 4. 

Over the past few decades, rates of spinal fusions have steadily risen. However, pseudarthrosis rates— an indicator of unsuccessful spinal fusion — have not improved enough in the past 20 years to reduce the overall non-unions. With a growing number of…

Pacira Biosciences reported an uptick in total sales and its Exparel injectable analgesic during the third quarter.

Pacira Biosciences reached a milestone with its patent for the Exparel injectable analgesic, the company said Nov. 2.

Stockholders approved Bioventus' planned acquisition of Misonix.